Archives
Verapamil Targets Txnip in Osteoporosis
2026-09-16
The reference study presents verapamil as a repurposing candidate for osteoporosis by linking TXNIP genetic variation and drug-mediated Txnip suppression to bone remodeling. Its combination of human association data, cell-based assays, transcriptomics, and ovariectomy-mouse experiments identifies distinct ChREBP-Txnip mechanisms in osteoclasts and osteoblasts, while remaining preclinical.
Resveratrol, CAFs, and Breast Cancer Hybrid Organoids
2026-09-16
A 2025 study used patient-derived breast cancer organoids combined with cancer-associated fibroblasts to model microenvironment-mediated drug protection. Resveratrol inhibited organoid growth, removed the fibroblast-associated growth advantage, and reduced CAF-associated VCAN and TGF-β expression, supporting organoid co-culture as a more informative context for proliferation studies.
Catalpol: A Neurovascular Unit Research Framework
2026-09-15
Catalpol, also known as Catalpinoside, offers a multi-pathway framework for studying neurovascular unit recovery after ischemic injury. This article translates key preclinical findings into practical assay, dosing, and interpretation decisions while distinguishing mechanistic evidence from broader disease-model applications.
From LDHA Mechanism to Stronger RCC Evidence
2026-09-15
Gingerenone A offers a compelling metabolic strategy for restoring sunitinib sensitivity in renal cell carcinoma. This thought-leadership analysis explains how rigorous western blot chemiluminescence detection can connect LDHA, lactate, HIF-1α, and angiogenic signaling to a more defensible translational evidence chain.
Catalpol: Mechanisms and Preclinical Research
2026-09-14
Catalpol, also called Catalpinoside in some research sources, is a Rehmannia-derived iridoid glycoside with multi-pathway preclinical activity. Its strongest research value is as a mechanism-oriented tool for neuroprotection research, ischemic stroke models, osteoporosis animal models, and inflammation-linked organ injury—not as a clinically established therapy.
Protease Inhibitor Cocktail: MS-SAFE Extraction
2026-09-14
Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) helps limit endogenous proteolysis during cell and tissue extraction, with an AEBSF-free formulation intended for mass spectrometry workflows. It is suitable for crude lysates and biochemical sample preparation, but it should not be treated as a universal inhibitor, a complete phosphatase-inhibitor system, or a validated live-cell treatment without additional testing.
Arachidonic Acid for Reliable Cell Assays
2026-09-13
A practical, scenario-based guide to using Arachidonic Acid (SKU C4223) in cell viability, proliferation, and cytotoxicity workflows. It addresses solvent compatibility, concentration design, pathway interpretation, vendor selection, and evidence limitations for reproducible lipid-signaling experiments.
Rucaparib, Splicing, and PARP Sensitivity
2026-09-12
Rucaparib (AG-014699, PF-01367338) offers a practical framework for studying how DNA repair state, radiation response, transporter biology, and spliceosome regulation shape PARP inhibitor sensitivity. Integrating product intelligence with a 2024 Nature Communications study on SmD2 acetylation, this article outlines translational experiments that connect HCC spliceosome biology with prostate cancer radiosensitization while distinguishing evidence from forward-looking hypotheses.
Isochlorogenic Acid A: From Molecule to Wound Repair
2026-09-11
Isochlorogenic acid A is moving from natural-product discovery toward formulation-led wound-repair research. This article examines its chemistry, Fe(III)-coassembled hydrogel evidence, experimental controls, translational limits, and strategic next steps for reproducible anti-infection, immunology, and inflammation research.
DiscoveryProbe Immunology/Inflammation Compound Library
2026-09-11
Convert a curated 295-compound collection into actionable immune pathway profiling, target validation, and phenotypic inflammation screening data. This workflow combines pre-dissolved small molecules with multiplex PBMC flow cytometry to separate pathway modulation, immune-cell activation, and nonspecific toxicity.
EZH2 Inhibition in HPV-Associated Cervical Cancer
2026-09-10
The reference study evaluates EPZ6438 and ZLD1039 as EZH2 inhibitors in HPV-positive and HPV-negative cervical cancer models, combining proliferation, apoptosis, cell-cycle, molecular, and chorioallantoic membrane readouts. Its main contribution is linking EZH2 inhibition with reduced HPV16 E6/E7 expression, increased p53 and Rb signals, epithelial-marker recovery, and stronger activity of EPZ6438 in HPV-positive cells, while also defining the limits of this preliminary evidence.
IAM LC vs LEKC for Pulmonary Drug Permeability
2026-09-10
This 2024 Journal of Chromatography A study provides a direct comparison of immobilised artificial membrane liquid chromatography and liposome electrokinetic capillary chromatography for modelling drug–membrane partitioning and pulmonary permeability. LEKC more closely reflected apparent lung permeability for the tested compounds, whereas IAM LC offered broader compound coverage and simpler, more automation-friendly analysis.
HyperFluor 488 Goat Anti-Rabbit IgG Guide
2026-09-09
HyperFluor 488 Goat Anti-Rabbit IgG provides fluorescent detection of rabbit primary antibodies in immunofluorescence, immunocytochemistry, fluorescence microscopy, and flow cytometry. It should not be used to detect non-rabbit primary antibodies or treated as a directly labeled primary antibody, and its sodium azide-containing buffer requires compatibility review for live-cell workflows.
Cisapride as a Dual-Readout Cardiac Stressor
2026-09-09
Cisapride (R 51619) offers a mechanistically informative challenge for cardiac electrophysiology research. This article presents a dual-readout framework that connects 5-HT4 receptor signaling, hERG channel inhibition, high-content imaging, and deep-learning phenotyping.
Polyploid Giant Cancer Macrophages in Blood
2026-09-08
The reference study characterizes circulating cancer-associated macrophage-like cells (CAMLs) as phagocytic polyploid giant cells with mixed myeloid, epithelial, and endothelial features. In a prospective multi-institutional cohort, CAMLs correlated with disease progression and spread, supporting their investigation as blood-based indicators of metastatic biology while leaving their cellular origin and causal role unresolved.
606 records 8/41 page Previous Next First page 上5页 678910 下5页 Last page